Skip to main content

Obesity &Amp; Overweight

Metabolic Diseases
3
Pipeline Programs
5
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.

$70.5B marketMature↑ Growing30 products15 companies

Key Trends

  • GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
  • SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
  • Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins

Career Verdict

Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
#2OZEMPICGrowing
$9.2B
Novo Nordisk·Peak12.4yr
#3JARDIANCEGrowing
$8.8B
#5FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

FXa Inhibitors (Anticoagulants)
$18.3B(26%)

stable, mature franchise

GLP-1 Agonists
$18.2B(26%)

rapid growth, expanding indications

SGLT2 Inhibitors
$9.4B(13%)

growing, cardio-renal expansion

Insulin Analogs
$7.8B(11%)

stable, generics pressure

DPP-4 Inhibitors
$5.4B(8%)

declining, patent cliff 2027

Career Outlook

Growing

Metabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.

Breaking In

Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.

For Experienced Professionals

Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.

In-Demand Skills

Commercial acumen and healthcare economics (GLP-1 market dynamics)Regulatory affairs (label expansion, indication creep for SGLT2/GLP-1)Digital health and CGM/insulin device experienceReal-world evidence generation and health outcomes research

Best For

Brand Manager (peak-cycle GLP-1 products)Medical Science Liaison (cardio-renal expansion)Market Access / Health Economics (SGLT2 outcomes)Commercial Operations (launch support for next-gen)

Hiring Landscape

$153K-$274K

Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.

574
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

270Growing
154Growing
42Stable
38Stable

By Department

Commercial(29%)
$220K
Engineering(22%)
$197K
Manufacturing(8%)
$274K
Clinical Operations(4%)
$153K

Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
2 programs
2
UBT251Phase 21 trial
UBT251 Injection 2.0 mg and UBT251 Injection PlaceboPhase 21 trial
Active Trials
NCT07134335Recruiting180Est. Jul 2030
NCT07177469Active Not Recruiting205Est. Dec 2025
Rona Therapeutics
Rona TherapeuticsChina - Shanghai
1 program
1
RN3161Phase 1/21 trial
Active Trials
NCT07245771Recruiting104Est. Aug 2027
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Chia seedsN/A1 trial
Active Trials
NCT07146958Active Not Recruiting24Est. Jun 2026
Medtronic
MedtronicNJ - Phillipsburg
1 program
GetReady applicationN/A1 trial
Active Trials
NCT07297342Recruiting200Est. Jun 2027
MindRank
MindRankChina - Shanghai
1 program
MDR-001PHASE_13 trials
Active Trials
NCT07550634Not Yet Recruiting32Est. Oct 2026
NCT07550621Not Yet Recruiting28Est. Jun 2026
NCT07110766Not Yet Recruiting24Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
BiocorpUBT251
BiocorpUBT251 Injection 2.0 mg and UBT251 Injection Placebo
Rona TherapeuticsRN3161
MindRankMDR-001
MindRankMDR-001
MindRankMDR-001
Human BioSciencesChia seeds
MedtronicGetReady application

Clinical Trials (8)

Total enrollment: 797 patients across 8 trials

UBT251 Injection Phase II Clinical Study (CKD)

Start: Sep 2025Est. completion: Jul 2030180 patients
Phase 2Recruiting
NCT07177469BiocorpUBT251 Injection 2.0 mg and UBT251 Injection Placebo

UBT251 Injection Phase II Study (Overweight or Obesity)

Start: Mar 2025Est. completion: Dec 2025205 patients
Phase 2Active Not Recruiting

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Start: Nov 2025Est. completion: Aug 2027104 patients
Phase 1/2Recruiting

Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment

Start: Jun 2026Est. completion: Oct 202632 patients
Phase 1Not Yet Recruiting

Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

Start: May 2026Est. completion: Jun 202628 patients
Phase 1Not Yet Recruiting

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

Start: Aug 2025Est. completion: Oct 202524 patients
Phase 1Not Yet Recruiting

Soup and Bread Recipe Impacts on Ingestive Behavior

Start: Aug 2025Est. completion: Jun 202624 patients
N/AActive Not Recruiting
NCT07297342MedtronicGetReady application

A Prospective Randomnised Controlled Trial Comparing Overall Patient Compliance in a Bariatric Surgical Pathway Using the Standard Versus a More Intensified and Interactive Version of the "Get Ready" Smartphone Application.

Start: Apr 2025Est. completion: Jun 2027200 patients
N/ARecruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 797 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.